Aurobindo Pharma reports Q3 net loss of Rs 28.54 cr – MSN India

Commenting on the results, Aurobindo Pharma Chairman Ramprasad Reddy said: “The current fiscal year has been challenging on account of full impact of the USFDA alert on our Unit 6 Cephalosporin manufacturing facility and mark-to-market loss on foreign …

Leave a Reply

Your email address will not be published.